Bijuva vs. Bijuve

See how Bijuva and Bijuve compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Bijuva and Bijuve are both oral capsules combining bioidentical estradiol and progesterone, FDA-approved in 2018 for hot flashes in women with a uterus.

  • The two share the same active ingredients, the same two dose strengths, and roughly the same monthly cost, so day-to-day use is nearly identical.

  • The real differences show up in how each label is organized: Bijuva spells out specific contraindications, while Bijuve groups its risks under formal boxed warnings.

Bijuva vs. Bijuve Drug Summary

Bijuva

Bijuva is a combination hormone therapy capsule containing bioidentical estradiol and progesterone, FDA-approved in 2018 to treat moderate to severe hot flashes caused by menopause in women who still have a uterus. It's taken once daily by mouth with food, at one of two dose strengths.

Bijuve

Bijuve is also an oral capsule combining bioidentical estradiol and progesterone, approved in 2018 for the same use: moderate to severe hot flashes of menopause in women with a uterus. It's taken once daily at one of two matching dose strengths.

Bijuva vs. Bijuve Side Effects

Bijuva

Most common
breast tenderness (up to 10.4%)
headache (up to 4.0%)
vaginal bleeding (up to 3.4%)
nausea (up to 3.5%)

Bijuve

Most common
breast tenderness (up to 10.4%)
headache (up to 3.4%)
vaginal bleeding (up to 3.4%)
vaginal discharge (up to 3.4%)

Bijuva vs. Bijuve Dosage

Bijuva

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg/100 mg once daily At the start
Maximum dose 1 mg/100 mg once daily If needed
Dose changes 1 increase As tolerated

Bijuve

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg/100 mg once daily At the start
Maximum dose 1 mg/100 mg once daily If needed
Dose changes 1 increase As tolerated

Bijuva vs. Bijuve Indications

Bijuva

Bijuva is FDA-approved specifically for moderate to severe hot flashes and night sweats linked to menopause in women who have a uterus. It is not approved to prevent heart disease, stroke, or dementia, and it should not be used during pregnancy or by women without a uterus.

  • Moderate to severe hot flashes (vasomotor symptoms) of menopause

  • For women with a uterus, since progesterone protects the uterine lining

  • Not approved for cardiovascular or dementia prevention

  • Not approved for use during pregnancy

Bijuve

Bijuve is FDA-approved for the same core use: moderate to severe vasomotor symptoms of menopause in women who have a uterus. Like Bijuva, it is not approved to prevent heart disease, stroke, or dementia, and it is not intended for women who do not have a uterus.

  • Moderate to severe hot flashes (vasomotor symptoms) of menopause

  • For women with a uterus, since progesterone protects the uterine lining

  • Not approved for cardiovascular or dementia prevention

  • Not intended for women who do not have a uterus

Bijuva vs. Bijuve Pros and Cons

Bijuva

Bijuva's label breaks out side effect rates by each dose strength and spells out specific contraindications, such as active blood clots or a history of breast cancer. It has no generic version yet, and the capsule needs a high-fat meal for full progesterone absorption.

Pros

  • Side effect data broken out by each dose strength (0.5 mg vs 1 mg)

  • Contraindications spelled out explicitly, not just as boxed warnings

  • Specific food guidance provided for consistent absorption

Cons

  • No generic version currently available

  • Requires a high-fat meal for full progesterone absorption

  • Breast tenderness reported in up to 10.4% at the higher dose

Bijuve

Bijuve's label presents its cardiovascular, cancer, and dementia risks as formal boxed warnings rather than a detailed contraindications list. It uses a single combined side effect rate rather than breaking results out by dose strength.

Pros

  • Cardiovascular, cancer, and dementia risks grouped under clear boxed-warning headings

  • Simpler single-rate side effect summary, easier to scan quickly

  • Shorter, more focused list of restricted uses

Cons

  • Side effects reported as one combined rate, not split by dose strength

  • Boxed-warning format can read as more alarming than a contraindication list

  • Doesn't spell out specific contraindications like active clots or breast cancer history

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.